Enrollment Closure -- Trial 1182.58: An Open-Label Safety Study (OLSS)
Trial 1182.58 evaluates the safety of tripranavir plus ritonavir when used in combination with other agents for the treatment of patients with HIV who have failed and/or are intolerant to combination antiretroviral therapy and have limited treatment options. The enrollment of new patients in the OLSS will cease once the tipranavir EAP initiates. Enrollment in the OLSS will remain open only for patients ages 13 to
Back to The Nexus Fall 2004 contents page.
This article was provided by American Academy of HIV Medicine. It is a part of the publication The Nexus.